MEC (Mitoxantrone, Etoposide and Intermediate Dose Cytarabine): An Effective Induction Regimen for Previously Untreated Acute Non-Lymphocytic Leukemia

References

• Champlin R. E., Gale R. P. Acute myelogenous leukemia: Recent advances in therapy. Blood 1987; 69: 1551–1562
   PubMed Web of Science ®Google Scholar
• Legha S. S., Keating M. J., McCredie K. B. Evaluation of AMSA in previously treated patients with acute leukemia: Results of therapy in 109 adults. Blood 1982; 60: 484–490
   PubMed Web of Science ®Google Scholar
• Prentice H. G., Robbins G., Ma D. D. F. Mitoxantrone in relapsed and refractory acute leukemia. Semin. Oncol. 1984; 11: 32–35
   PubMed Web of Science ®Google Scholar
• Lazzarino M., Morra E., Alessandrino E. P. Mitoxantrone and Etoposide: An effective regimen for refractory or relapsed acute myelogenous leukemia. Eur. J. Haematol. 1989; 43: 411–416
   PubMed Web of Science ®Google Scholar
• Harosseau J. L., Hurteloup P., Reiffers J. Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia. Cancer Treat. Rep. 1987; 71: 1991–1992
   Google Scholar
• Herzig R. H., Lazarus H. M., Wolff S. N. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute non-lymphoblastic leukemia. J. Clin. Oncol. 1985; 3: 992–997
   PubMed Web of Science ®Google Scholar
• Amadori S., Arcese W., Isacchi G., Meloni G., Petti M. C., Monarca B., Testi A. M., Mandelli F. Mitoxantrone, Etoposide and intermediate-dose Cytarabine: An effective and tolerable regimen for the treatment of refractory acute leukemia. J. Clin. Oncol. 1991; 9: 1210–1214
   PubMed Web of Science ®Google Scholar
• Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A. G., Gralnick H. R., Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-British Cooperative Group. Ann. Intern. Med. 1985; 103: 620–624
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Anderson K., Rai K., Cuttner J., Yates J., Du Pre E., Holland J. F. The frequency of long-term remission in patients with acute myelogenous leukemia treated with conventional maintenance chemotherapy: A study of 760 patients with a minimal follow-up time of 6 years. Br. J. Haematol. 1989; 71: 189–194
   PubMed Web of Science ®Google Scholar
• World Health Organization. 1979, WHO hand book for reporting results of Cancer treatment: WHO Publication 38, Geneva
   Google Scholar
• Mandelli F., Rees J. K. H., Gorin N. C., Prentice H. G. Post remission treatment in acute myeloid leukemia: Chemotherapy or autologous or allogeneic bone marrow-transplantation. Haematologica 1990; 75: 203–211
   PubMedGoogle Scholar
• Bernasconi C. Current status and potential role of Mitoxantrone in the treatment of acute leukemia and malignant lymphomas. New Trends in the Therapy of Leukemia and Lymphoma 1988; 3: 49–53
   Google Scholar
• Hiddemann W., Kreutzmann H., Straif K., Ludwig W. D., Mertelsmann R., Donhuijsen-Ant R., Lengfelder E., Arlin Z., Buchner T. High-dose cytosine arabinoside and mitoxantrone: A highly effective regimen in refractory acute myeloid leukemia. Blood 1987; 69: 744–749
   PubMed Web of Science ®Google Scholar
• Link H., Freund M., Diedrich H. Mitoxantrone, cytosine arabinoside and VP16 in 36 patients with relapsed and refractory acute myeloid leukemia. Humutol Blurtrunsfus. 1990; 33: 322–325
   Google Scholar
• Ho A. D., Lipp T., Enninger G. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia. An Active and well tolerated regimen. J. Clin. Oncol. 1988; 6: 213–217
   PubMed Web of Science ®Google Scholar
• Archimbaud E., Leblond V., Meuricette M., Cordonnier C., Fenaux P., Travade P., Dreyfus S., Jaubert J., Devaux J., Fiere D. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. Blood 1991; 77: 1894–1900
   PubMed Web of Science ®Google Scholar
• La Tagliata R., Petti M. C., Aloe Spiriti M. A., Meloni G., Sgadari C., Torromeo C., Vegna M. L., Mandelli F. High-dose ARA-C and m-AMSA in the treatment of refractory acute non lymphocytic leukemia. Haematologica 1990; 75: 249–251
   PubMedGoogle Scholar
• Bolwell B. J., Cassileth P. A., Gale R. P. High dose cytarabine: a review. Leukemia 1988; 2: 253–60
   PubMed Web of Science ®Google Scholar
• Mayer R. J., Davis R. D., Schiffer C. A., Berg D. T., Powell B. L., Schulman P., Omura G. A., Moore J. O., McIntyre O. R., Frei E. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med. 1994; 331: 896–903
   PubMed Web of Science ®Google Scholar
• Bishop J. F., Young G. A., Szer J., Mattews J. P. Randomized trial of high dose cytosine arabinoside (ARA-C) combinations in induction in acute myeloid leukemia. Proceedings of ASCO, San Diego. M. C. Perry. 1992; Vol. 11: 849
   Google Scholar
• Weick J., Kopecky K., Appelbaum F., Head D., Elias L., Kingsbury L., Daniels D., Balcerzak S. P., Mills G. M., Hynes H. E., Coltman C., Grever M. A randomized investigations of high-dose (HDAC) versus standard dose (SDAC) cytosine arabinoside with daunorubicin (DNR) in patients with acute myelogenous leukemia. Proceedings of ASCO (San Diego), M. C. Perry. 1992; 11: 856
   Google Scholar
• Battista R., Bassan R., D'Emilio A., Dragone P., Viero P., Dini E., Barbui T. Short-term remission induction and consolidation therapy for adult acute myelogenous leukemia. Hematol. Oncol. 1991; 9(1): 43–52
   Web of Science ®Google Scholar
• Wiernik P. H., Banks P. L., Case P. C., Jr, Arlin Z. A., Periman P. O., Todd M. B., Ritch P. S., Enck R., Weitberg A. B. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79(2)313–319
   PubMed Web of Science ®Google Scholar
• Vogler W. R., Valzer-Garcia E., Weiner R., Flaum M. A., Bartolucci A. A., Omura G. A., Gerber M. C., Banks P. L. C. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia. A Southeastern Cancer Study Group. J. Clin. Oncol. 1992; 10: 1103–1111
   PubMed Web of Science ®Google Scholar
• Clarkson B., Berman E., Little G., Andreef M., Kempin S., Kolitz J., Gabrilove J., Arlin Z., Mertelsmann R., Cunningham I., Castro-Malaspina H., Gulati S., O'Reilly R., Gee T. Update in clinical trial of chemotherapy and bone marrow transplantation in acute myelogenous leukemia in adults at Memorial Sloan-Kettering Cancercenter (MSKCC) 1966–1989. From UCLA Symposium Workshop on AML 11/89 (WZ90). UCLA Symposium on molecular biology-new series. 1990; 239–272, 134
   Google Scholar
• Willemze R., Jager V., Jehn U. Intermediate and high-dose ARA-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia. An EORTC leukemia Cooperative Group phase II study. Eur. J. Cancer Clin. Oncol. 1988; 24(11)1721–1725
   PubMedGoogle Scholar
• Mandelli F., Vegna M. L., Avvisati G. A randomized study of the efficacy of post-consolidation therapy in adult acute nonlymphocytic leukemia: A report of the Italian Cooperative Group GIMEMA. Ann. Hematol. 1992; 64: 166–172
   PubMed Web of Science ®Google Scholar
• Hansen O. P., Pedersen-Bjergaard J., Ellegaard J., Brincker H., Boesen A. M., Christensen B. E., Drivsholm A., Hippe E., Jans H., Jensen K. B., Killman S. A., Jensen M. K., Karle H., Laursen B., Nielsen J. B., Nissen N. I., Thorling K. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: A Danish national phase III trial: The Danish Society of Hematology Study Group on ANLL, Denmark. Leukemia 1991; 5(6)510–516
   PubMed Web of Science ®Google Scholar
• Berman E., Heller G., Santorsa J., McKenzie S., Gee T., Kempin S., Gulati S., Andreef M., Kolite J., Gabrilove J., Reich L., Mayer K., Keefe D., Trainor K., Schluger A., Penenberg D., Raymond V., O'Reilly R., Jhanwar S., Young C., Clarkson B. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666–1674
   PubMed Web of Science ®Google Scholar